NuVision ICE Catheter: Positive Results From First-in-human Feasibility Study Reported At 2020 TCT Conference

October 14, 2020

NuVision ICE Catheter: Positive results from its first-in-human (FIH) feasibility study performed by principal investigator, Dr. Adrian Ebner, Head of the Cardiovascular Department at the Universidad Nacional de Asuncion in Asuncion, Paraguay was highlighted in an abstract presentation by Dr. Azeem Latib, Director of Interventional Cardiology and Structural Heart Interventions at the Montefiore Medical Center in New York, NY as part of the 32nd Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation. The news was announced today by Nuvera Medical.

“Initial clinical experience of the NuVision ICE Catheter supports safe and effective use with all primary and secondary safety and performance endpoints met and zero adverse events reported,” commented Dr. Latib. “This state-of-the-art 4D ultrasound technology will undoubtedly be the future of procedural guidance across a wide range of electrophysiology and structural heart procedures. I look forward to the benefit this advancement will bring to my practice and for my patients.”

One of the first virtually-supported clinical studies performed during the COVID-19 pandemic, the prospective, non-randomized, single-center FIH study investigated the feasibility of the NuVision™ ICE Catheter in visualizing anatomical structures in patients being evaluated for structural heart procedures such as atrial septal defect (ASD) or patent foremen ovale (PFO) closure, left atrial appendage (LAA) closure, and mitral or tricuspid valve repairs.

“The NuVision ICE Catheter provided me a completely new perspective in imaging of complex intracardiac structures and I could easily visualize the structures for catheter guidance,” stated Dr. Ebner. “All procedures were performed under conscious sedation and did not require intubation, which reduced overall length of stay, exposure to fluoroscopy and staffing demands. I believe NuVera’s novel solution has the potential to be an alternative to TEE for procedural guidance in structural heart interventions.”

“We are very pleased with the results of the initial patient experience and thank the outstanding clinical team for making this virtually-supported study a success,” said Todor Jeliaskov, President CEO of NuVera Medical. “We are happy to see the NuVision ICE Catheter simplified complex procedures for greater physician and patient benefit and look forward to building on this clinical experience as we prepare to bring our advanced imaging technology to market.”

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy